Discovery of novel tertiary amide derivatives as NEDDylation pathway activators to inhibit the tumor progression in vitro and in vivo
作者:Dong-Jun Fu、Jian Song、Ting Zhu、Xiao-Jing Pang、Sheng-Hui Wang、Yan-Bing Zhang、Bo-Wen Wu、Jun-Wei Wang、Xiaolin Zi、Sai-Yang Zhang、Hong-Min Liu
DOI:10.1016/j.ejmech.2020.112153
日期:2020.4
NAE1-Ubc12-Cullin1 NEDDylation via interacting with NAE1 directly. Furthermore, the activation of NEDDylation resulted in the degradation of inhibitor of apoptosis proteins (IAPs). Importantly, Ⅶ-31 inhibited tumor growth in xenograft models in vivo without the apparent toxicity. In summary, it is the first time to reveal that Ⅶ-31 deserves consideration for cancer therapy as a NEDDylation activator.
NEDDylation通路调节多种生理过程,与抑制剂不同,NEDDylation激活剂很少被研究。合成了新的酰胺衍生物,并评估了其对MGC803,MCF-7和PC-3细胞的抗增殖活性。其中,Ⅶ-31对MGC803细胞表现出最强的活性,IC 50值为94 nmol / L。细胞机制阐明,Ⅶ-31通过针对MGC803细胞的内在和外在途径抑制细胞活力,使细胞周期停滞在G2 / M期并诱导凋亡。另外,Ⅶ-31通过直接与NAE1相互作用激活了NAE1-Ubc12-Cullin1 NEDDylation。此外,NEDDylation的激活导致凋亡蛋白(IAPs)抑制剂的降解。重要的是,Ⅶ-31抑制了体内异种移植模型中的肿瘤生长,而没有明显的毒性。总之,这是首次揭示the -31作为NEDDylation激活剂值得用于癌症治疗。